Unlocking disease mechanisms with multiomic nanopore sequencing
)
In this knowledge exchange, we will explore the multifaceted applications of multiomic nanopore sequencing in disease research, with best-practice introductions to nanopore sequencing workflows and real-world case studies. Join us at 4pm UK time (11am EST).
First, Sayonika Mohanta (Market Segment Manager — Methylation) will introduce how multiomic nanopore sequencing data — spanning whole-genome sequencing, bulk and single-cell transcriptomics, methylation analysis, and 3D chromatin analysis — provides deeper insights into mechanisms of disease.
Next, Scott Hickey (Director - Genomic Applications) will present the use of whole-genome and single-cell transcriptome sequencing to study the adaptive immune response. He will share how, in a collaboration with Benhur Lee Laboratory (Icahn School of Medicine at Mount Sinai, USA), full-length immunoglobulin transcript sequences paired with a haplotype-resolved germline assembly from the same research sample provided a comprehensive view of personalised immune responses.
Finally, Art Rand (Research Scientist, Machine Learning) will share how multiomic nanopore sequencing techniques were used to study methylation and CTCF-dependent control of 3D chromatin structure in both normal and malignant haematopoiesis. This research, from Aaron Viny (Columbia University Irving Medical Center, USA), explores how chromatin architecture and cohesin mutations impact gene regulation and contribute to transcriptional dysregulation and transformation in blood cells.
In this webinar, participants will learn:
How multiomic nanopore sequencing approaches — integrating genomics, bulk and single-cell transcriptomics, chromatin conformation capture, and genomic variant and methylation data — can enhance research into mechanisms of disease
How whole-genome and single-cell transcriptome nanopore sequencing can be leveraged for novel antibody discovery and understanding immune response dynamics
How multiomic nanopore sequencing enables exploration of the relationship between 3D chromatin structure, cohesin complexes, and gene regulation in normal and malignant hematopoiesis
Meet the speakers
)
Sayonika Mohanta, Segment Manager – Methylation, Oxford Nanopore TechnologiesSayonika Mohanta is the Strategic Manager for Methylation and Human Epigenetics at Oxford Nanopore, where she leads innovative marketing strategies in genomics. With degrees in Bioengineering from UCLA and Chemical and Biomolecular Engineering from Johns Hopkins, she brings a strong academic foundation and extensive biotech experience to her role. Dedicated to bridging scientific research and industry, she ensures that groundbreaking genomic innovations reach and benefit the broader biotech community. At Oxford Nanopore, she is committed to fostering collaboration and knowledge sharing across the field.
)
Scott Hickey, Director - Genomic Applications, Oxford Nanopore TechnologiesScott Hickey is the Director of Commercial Applications at Oxford Nanopore Technologies, based in San Francisco, CA. His team runs pilot projects demonstrating the impact of Oxford Nanopore sequencing in rare disease, cancer, single cell, epigenetics, and metagenomics with sequencing and analysis expertise using the latest protocols and bioinformatics workflows. Scott received his PhD in Chemistry at the University of California, Berkeley, and did his post-doctoral research in cell biology at the University of California, San Francisco.
)
Art Rand, Research Scientist, Machine Learning, Oxford Nanopore TechnologiesArt was introduced to nanopore sequencing and Oxford Nanopore Technologies in graduate school where he was a member of Mark Akeson's lab (the UCSC nanopore group). He started as a wet-lab biochemist and transitioned to bioinformatics mid-way through the program. He started working on DNA methylation detection and classification with nanopores from the get-go. He lives in Santa Cruz, California and enjoys road cycling and backpacking in his free time.
